5. Psychedelic-Assisted Therapy and Novel Rapid Antidepressants

The treatment of bipolar depression remains one of the most difficult problems in clinical psychiatry. Existing first-line agents (quetiapine, lurasidone, lamotrigine, lithium) take weeks to produce meaningful improvement, and a substantial fraction of patients do not respond adequately to any available pharmacotherapy. This has generated intense interest in two classes of agents that work through fundamentally different mechanisms and produce effects within hours to days: ketamine and psilocybin. Both carry genuine promise and genuine risk for patients with bipolar disorder, and the evidence base for bipolar-specific use is far thinner than the enthusiasm surrounding these treatments.

5.1 Ketamine in Bipolar Depression

Ketamine (an NMDA receptor antagonist (a drug that blocks a specific type of glutamate receptor involved in learning, memory, and synaptic plasticity)) produces rapid antidepressant effects through a mechanism fundamentally different from serotonin-based antidepressants. It triggers a glutamate surge that promotes rapid synaptic plasticity and BDNF release, producing measurable mood improvement within hours rather than weeks. Efficacy data. In the only randomized controlled trial of ketamine specifically in bipolar depression, Diazgranados et al. (2010, Archives of General Psychiatry) reported a response rate of 71% for ketamine versus 6% for placebo (n=18 crossover), with an effect size of d = 0.52 (95% CI: 0.28-0.76) at 40 minutes post-infusion, with effects persisting through day 2. A subsequent meta-analysis pooling both unipolar and bipolar RCTs (McGirr et al., 2015, Psychological Medicine) found a number needed to treat (NNT) of 3 at 24 hours (OR = 9.10, 95% CI: 2.28-36.35). The large effect in the Diazgranados trial should be interpreted cautiously given the small sample size. However, when bipolar depression patients are analyzed separately, the numbers are more modest. In a bipolar-specific maintenance study (n=45, 518 patient-months), acute induction with twice-weekly ketamine (over 2-4 weeks) produced a 39% response rate (≥50% MADRS reduction) and 13% remission rate (MADRS < 10) (Santucci et al., 2024, Journal of Clinical Psychiatry). Manic switching risk. During the acute induction phase, manic switching was zero (a reassuring signal (Santucci et al., 2024, Journal of Clinical Psychiatry). During longer-term maintenance dosing (weekly to biweekly), 13 of 45 patients (28.9%) experienced manic or hypomanic events, totaling 16 events over the study period. The median time to first manic event was 266 days, exceeding the median treatment duration of 95 days, and 15 of 16 events were mild to moderate with none requiring hospitalization (Santucci et al., 2024, Journal of Clinical Psychiatry). The investigators interpreted these events as likely reflecting natural bipolar cycling rather than direct drug-induced switching, a reasonable interpretation, but one that highlights the challenge of disentangling treatment effects from the underlying disease in a condition defined by episodic mood instability. Regulatory status. Esketamine (Spravato, the S-enantiomer of ketamine, marketed by Johnson & Johnson) received FDA approval in 2019 for treatment-resistant unipolar depression; its use for bipolar depression is off-label. Racemic IV ketamine is widely used off-label for bipolar depression in clinical practice. NICE (TA854) recommends esketamine for unipolar TRD but does not endorse it for bipolar depression due to insufficient RCT evidence (FDA approval data; NICE TA854). There are no head-to-head RCTs comparing IV racemic ketamine versus intranasal esketamine in bipolar cohorts. The clinical choice between them is driven by access and insurance rather than comparative efficacy data. Where ketamine sits in the bipolar depression treatment algorithm. Ketamine is not a first-line, second-line, or even conventional third-line agent for bipolar depression. Guideline-concordant first-line treatments (quetiapine, lurasidone, lamotrigine, lithium) should be tried first, and the clinician should have documented failure of or intolerance to multiple adequate trials before considering ketamine referral. The two clinical scenarios where ketamine's rapid onset provides the most value are: (1) acute, severe bipolar depression with active suicidal ideation where the 4 to 6 week onset of standard agents is clinically dangerous, and (2) treatment-resistant bipolar depression where multiple guideline-concordant agents have failed and the patient is functionally incapacitated. Contextualizing the 39% response rate. The bipolar-specific response rate of 39% is often perceived as disappointing compared to the 71% rate cited in mixed cohorts, but context matters. By the time a bipolar patient is being considered for ketamine, they have typically failed multiple prior treatments. In treatment-resistant populations, 39% response and 13% remission compare favorably to many augmentation strategies. For rough comparison (noting that these numbers come from different study designs, patient populations, and outcome measures and should not be directly equated), rTMS achieves approximately 47% response in bipolar depression (Section 6), lamotrigine's acute effect size is small (SMD = 0.155), and pramipexole achieves approximately 62% response in small pooled RCTs but requires weeks of slow titration. Ketamine's unique advantage is speed: measurable improvement within hours to days rather than weeks to months. IV racemic ketamine versus intranasal esketamine for bipolar patients. No head-to-head trials exist in bipolar cohorts. In unipolar depression, IV racemic ketamine may have a modestly higher response rate, but the comparison is complicated by differences in dosing, bioavailability, and study design. Practical considerations often drive the choice: intranasal esketamine (Spravato) has REMS certification requirements and can only be administered in certified healthcare settings with a 2-hour post-dose monitoring period, but it may be partially covered by insurance for patients with a unipolar TRD diagnosis. IV racemic ketamine is administered in specialized ketamine clinics, is rarely covered by insurance for any psychiatric indication, and typically costs $400 to $800 per infusion out of pocket. A typical acute course involves 6 infusions over 2 to 3 weeks. Maintenance infusions (every 2 to 4 weeks) are needed to sustain response, as the antidepressant effects of a single infusion typically fade within 1 to 2 weeks. Monitoring protocol for bipolar patients receiving ketamine (clinical convention based on observed safety signals, not a formal guideline recommendation). Any clinician referring a bipolar patient for ketamine should verify that the administering provider uses standardized mood monitoring at every visit: the YMRS (Young Mania Rating Scale) or equivalent for emerging manic symptoms, and the C-SSRS (Columbia Suicide Severity Rating Scale) for suicidality tracking. The patient's mood stabilizer should be maintained throughout the ketamine course. If manic or hypomanic symptoms emerge during the maintenance phase (which occurred in 28.9% of patients in the largest bipolar-specific study), the treating team needs a predetermined plan: whether to pause ketamine, increase the mood stabilizer, or both. Dissociative side effects during infusion (feeling detached, perceptual distortions) are expected and typically resolve within 1 to 2 hours; they are not an indication to discontinue treatment. The conversation with patients. "Ketamine works through a completely different brain pathway than your current medications and can produce improvement within hours to days instead of weeks. In one study of 45 bipolar depression patients specifically, about 39% responded, which is meaningful for a treatment-resistant condition. The main concern we monitor for is the possibility of triggering hypomanic or manic symptoms, which happened in about 29% of patients during longer-term treatment in that same study, though most of these episodes were mild. The treatment is not yet FDA-approved for bipolar depression, it warrants ongoing infusions to maintain the benefit, and it is expensive if not covered by insurance. I want you to have realistic expectations: this is not a cure, and it warrants continued infusions to maintain the benefit."

5.2 Psilocybin in Bipolar Disorder

The entire published evidence for psilocybin in bipolar disorder consists of a single trial with 15 participants. Before reviewing the details, clinicians should understand: this is hypothesis-generating data, not practice-changing evidence. Psilocybin (a partial agonist at the serotonin 5-HT2A receptor (the receptor through which most classic psychedelics produce their effects), with secondary affinities for 5-HT1A, 5-HT1B, and 5-HT2C receptors) produces its antidepressant effects through a mechanism involving glutamate surges in the prefrontal cortex and hippocampus and increased synaptic density: SV2A density increased by 9.24% in the hippocampus and 6.10% in the prefrontal cortex for up to 7 days post-intervention (psilocybin neurobiological mechanism data; Smart et al., 2021). These synaptic changes are accompanied by disruption of the default mode network, the brain's resting-state network associated with self-referential thinking and rumination, which may underlie the therapeutic effect. Bipolar-specific trial data. The total published evidence for psilocybin in bipolar disorder consists of a single trial with 15 participants, all with bipolar II disorder (excluding anyone with a lifetime history of full mania or psychosis) (NCT05065294; bipolar II psilocybin trial). Within this highly selected sample, the safety signal was encouraging: zero instances of manic, hypomanic, or mixed-state switching during the acute 3-week post-dosing phase. Antidepressant effects were rapid and robust, mirroring the large effect sizes seen in unipolar treatment-resistant depression trials. Nine of 15 participants (60%) discontinued baseline mood stabilizers and antidepressants for the entire 12-week study duration and maintained remission without pharmacotherapy (12-week follow-up data). These results are promising but should be interpreted with extreme caution. The sample is tiny. Follow-up is limited to 12 weeks. Participants were carefully screened to exclude anyone with bipolar I, psychotic features, or rapid cycling. The long-term durability of antidepressant effects beyond 12 weeks is unknown. This is hypothesis-generating data, not practice-changing evidence. A critical neurobiological difference from unipolar depression. Psilocybin produces fundamentally different effects on emotional processing depending on the underlying disorder. In unipolar treatment-resistant depression, SSRIs and psilocybin both decrease amygdala reactivity to negative emotional stimuli. In bipolar disorder, psilocybin appears to increase right amygdala reactivity, re-awakening emotional processing (amygdala reactivity comparison data). In a condition already characterized by emotional lability, impulsivity, and impaired prefrontal control, the combination of increased amygdala reactivity and default mode network disruption could theoretically precipitate mania. This is the core reason why bipolar I remains an exclusion criterion in all current psilocybin trials.

5.3 Critical Drug Interactions: The Lithium-Psychedelic Contraindication

Lithium and classic psychedelics: strongly contraindicated. An analysis of online psychedelic experience reports (Nayak et al., 2021, Pharmacopsychiatry) documented that 47% of lithium plus classic psychedelic co-administration cases involved seizures, 18% involved severe psychological crises, and 39% required emergency medical attention (Nayak et al., 2021, seizure risk analysis). A 47% seizure rate is unacceptable by any clinical standard. If a patient on lithium discloses intent to use psychedelics (whether through a clinical trial, a therapeutic retreat, or unsupervised use) the clinician must explicitly warn that lithium co-administration creates a life-threatening seizure risk. Lamotrigine and classic psychedelics: appears safe. In the same analysis (n=34 reports), lamotrigine co-administration produced zero seizures, and 65% of reports described no negative effect on the psychedelic experience (Nayak et al., 2021, lamotrigine data). This has led to preliminary interest in lamotrigine as a potential "coverage" agent for bipolar patients entering psychedelic protocols, maintaining mood stabilization while permitting the therapeutic experience. However, there is no RCT evidence supporting this strategy; it remains theoretical. MDMA and olanzapine: severe mortality risk. The research literature includes explicit warnings about co-administration of MDMA with olanzapine due to a severe mortality interaction (MDMA-olanzapine interaction warning). While MDMA-assisted therapy trials focus primarily on PTSD rather than bipolar disorder, clinicians must be aware that patients may pursue these treatments independently.

5.4 Naturalistic Use Versus Clinical Trials: A Stark Safety Gap

Survey data from 541 patients with bipolar disorder who used psilocybin outside of clinical settings found that 32.2% (174 respondents) reported new or worsening psychiatric symptoms (including hypomanic/manic symptoms, severe anxiety, and insomnia) and 3.3% required emergency medical services (Kopra et al., 2023, Journal of Psychopharmacology). Contrast this with the controlled clinical trial: zero acute switching events. The safety gap between naturalistic use and supervised clinical trials likely reflects differences in patient selection (clinical trials exclude high-risk phenotypes), dosing protocols, psychological preparation and support, and environmental control. The implication is clear: even if psilocybin eventually proves useful for carefully selected bipolar II patients, unsupervised use carries substantially higher risk.

5.5 Where the Evidence Stands and What Is Missing

The honest summary: ketamine has the stronger evidence base for bipolar depression, with larger sample sizes, longer follow-up, and established clinical infrastructure for administration. Psilocybin has generated exciting preliminary signals but is supported by a single 15-person trial in a highly selected bipolar II population. Neither agent has been tested in bipolar I depression in controlled trials. There are no data on pediatric or adolescent bipolar populations. The long-term maintenance strategies for both agents in bipolar disorder are uncharacterized. For clinicians, the current standard of care has not changed. Lurasidone, quetiapine, lamotrigine, and lithium remain first-line for bipolar depression per CANMAT/ISBD and APA guidelines. Ketamine may have a role in acute, severe bipolar depression (particularly when suicidality demands rapid response) but should be administered with close monitoring for manic symptoms and with the understanding that bipolar-specific response rates (39%) are notably lower than the rates typically cited from unipolar cohorts (71%). Psilocybin-assisted therapy for bipolar disorder is investigational and should occur only within specialized research protocols.

Clinical Pearl

What to say when a bipolar patient asks about ketamine or psilocybin: These are emerging treatments with real science behind them, not pseudoscience. Ketamine has the stronger evidence base, it can produce rapid improvement in bipolar depression, and controlled trials show minimal acute manic switching risk. However, during longer-term use, manic events occurred in about 29% of bipolar patients, and it remains unclear whether this reflects the treatment or the natural disease course. Psilocybin is further behind: the entire bipolar evidence base is a single 15-person trial, limited to bipolar II. The most critical safety fact is the lithium-psychedelic seizure risk: any patient on lithium must be explicitly told that combining lithium with classic psychedelics carries a 47% seizure rate. This is the one interaction that demands proactive disclosure regardless of whether the patient has asked about psychedelics, because patients may pursue these substances without telling their provider.

In plain language for families: ---

PsychHQ

Psychedelic-Assisted Therapy and Novel Rapid Antidepressants